Lynx DX, Inc is a leading provider of diagnostic testing services, specializing in prostate cancer risk assessment. Their flagship product, MyProstateScore 2.0, offers a comprehensive and highly accurate urine test that provides actionable data for both patients and healthcare providers. With a focus on simplicity and precision, Lynx DX aims to support positive public health by empowering individuals to make informed decisions about their prostate cancer care.
Utilizing a unique array of 18 genetic biomarkers, including the most specific prostate cancer biomarker available, MyProstateScore 2.0 delivers clear and concise patient risk reports. By combining clinical factors and advanced data models, Lynx DX ensures a 95-99% accurate prediction of cancer risk. With early detection being crucial for successful treatment, Lynx DX provides a non-invasive and reliable solution for personalized healthcare decision-making in prostate cancer screening.
Generated from the website